Canopy Growth (TSX:WEED) Stock: Should You Buy the Dip?

Canopy Growth Corp (TSX:WEED)(NYSE:CGC) stock fell sharply after its Q1 FY 2020 earnings, and there are few positives to glean as we look ahead to September.

| More on:
Female scientist in a hemp field checking plants and flowers, alternative herbal medicine concept

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Cannabis stocks were riding high, as we moved into the spring of 2019. The glow had returned after a rough post-legalization dip for the sector. Broader market turbulence has historically had a strong impact on cannabis stocks, and the late 2018 correction was no different. Unfortunately, this momentum has not lasted.

In the middle of spring, I’d warned investors that cannabis stocks were likely headed for a bout with the bear. The catalyst for this poor outlook was the revelation that cannabis sales had broadly disappointed to start 2019.

Scotiabank released a forecast that projected disappointing earnings for many of the top producers. The warnings have turned out to be accurate, as earnings have poured out in the spring and summer.

Canopy Growth (TSX:WEED)(NYSE:CGC) stock is the largest cannabis company by market cap on the TSX. Shares gained a second wind from mid-April into May. In late May, I’d discussed Canopy Growth’s impending Q4 and full-year earnings release and said that Canopy Growth was too pricey to pick up at the time.

The company released its first-quarter fiscal 2020 results on August 14. Shares fell after the release as Canopy Growth’s earnings disappointed analysts. The company posted a $1.28 billion loss, or $3.70 per share, in the first quarter, down significantly from a $91 million loss, or $0.40 per share, in Q1 fiscal 2019.

Canopy conceded that it was still likely three to five years away from profitability. This comes a month after former CEO Bruce Linton was pushed out, reportedly due to dissatisfaction in the company’s performance from Constellation Brands and other stakeholders.

It was not all bad news for Canopy Growth in the quarter. The company reported that it had increased dried cannabis sales 94% compared to Q4 fiscal 2019. Its international cannabis revenue rose 209% from the prior year.

Still, Canopy’s inability to turn improved sales in the wake of legalization into more significant revenue growth is concerning. The company is facing an uphill battle, as deteriorating margins and cash flow come into focus.

Canopy built massive inventory in preparation for legalization, which helped it get off to a fast start in late 2018. This led to positive sales initially, but the company has struggled to convert its greenhouse assets into grow operations as quickly as investors would have liked to see. The running of these facilities, which were going off zero production, led to an industry-low gross margin of 15%.

Is there any reason to jump on Canopy stock right now?

Shares of Canopy have plunged 23% over the past month as of close on August 19. The company is years away from profitability, and the more analysts focus on financial metrics, the more shareholders will find themselves frustrated.

Even more alarming are some of the broader indicators in the sector. Canada has failed to weed out the black market, and now that legal prices are rising, many buyers have simply moved back to underground channels. Demand has fallen below estimates on the domestic front. Disappointment is the word that comes to mind as we approach the one-year anniversary of recreational legalization.

Canopy stock had an RSI of 25 as of close on August 19. This puts the stock in technically oversold territory, but there are too many hurdles for me to consider jumping on the stock in the late summer.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Ambrose O'Callaghan has no position in any of the stocks mentioned. Scotiabank is a recommendation of Stock Advisor Canada.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »